Literature DB >> 32486476

Matching between Donors and Ulcerative Colitis Patients Is Important for Long-Term Maintenance after Fecal Microbiota Transplantation.

Koki Okahara1, Dai Ishikawa1, Kei Nomura1, Shoko Ito1, Keiichi Haga1, Masahito Takahashi1, Tomoyoshi Shibuya1, Taro Osada1, Akihito Nagahara1.   

Abstract

We previously demonstrated that fresh fecal microbiota transplantation (FMT) following triple antibiotic therapy (amoxicillin, fosfomycin, metronidazole (AFM); A-FMT) resulted in effective colonization of Bacteroidetes species, leading to short-term clinical response in ulcerative colitis (UC). Its long-term efficacy and criteria for donor selection are unknown. Here, we analyzed the long-term efficacy of A-FMT compared to AFM monotherapy (mono-AFM). AFM was administered to patients with mild to severe UC for 2 weeks until 2 days before fresh FMT. Clinical response and efficacy maintenance were defined by the decrease and no exacerbation in clinical activity index. The population for intention-to-treat analysis comprised 92 patients (A-FMT, n = 55; mono-AFM, n = 37). Clinical response was observed at 4 weeks post-treatment (A-FMT, 56.3%; mono-AFM, 48.6%). Maintenance rate of responders at 24 months post-treatment was significantly higher with A-FMT than mono-AFM (p = 0.034). Significant differences in maintenance rate according to the age difference between donors and patients were observed. Additionally, sibling FMT had a significantly higher maintenance rate than parent-child FMT. Microbial analysis of patients who achieved long-term maintenance showed that some exhibited similarity to their donors, particularly Bacteroidetes species. Thus, A-FMT exhibited long-term efficacy. Therefore, matching between donors and UC patients may be helpful in effectively planning the FMT regimen.

Entities:  

Keywords:  antibiotic-fecal microbiota transplantation; donor-patient matching; ulcerative colitis

Year:  2020        PMID: 32486476     DOI: 10.3390/jcm9061650

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  14 in total

Review 1.  Antibiotics for the induction and maintenance of remission in ulcerative colitis.

Authors:  Morris Gordon; Vassiliki Sinopoulou; Ciaran Grafton-Clarke; Anthony K Akobeng
Journal:  Cochrane Database Syst Rev       Date:  2022-05-18

Review 2.  Evolutionary Insights Into Microbiota Transplantation in Inflammatory Bowel Disease.

Authors:  Xiaoli Wang; Jingwen Zhao; Yuanhang Feng; Zelin Feng; Yulin Ye; Limin Liu; Guangbo Kang; Xiaocang Cao
Journal:  Front Cell Infect Microbiol       Date:  2022-06-22       Impact factor: 6.073

3.  Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.

Authors:  Maribeth R Nicholson; Erin Alexander; Sonia Ballal; Zev Davidovics; Michael Docktor; Michael Dole; Jonathan M Gisser; Alka Goyal; Suchitra K Hourigan; M Kyle Jensen; Jess L Kaplan; Richard Kellermayer; Judith R Kelsen; Melissa A Kennedy; Sahil Khanna; Elizabeth D Knackstedt; Jennifer Lentine; Jeffery D Lewis; Sonia Michail; Paul D Mitchell; Maria Oliva-Hemker; Tiffany Patton; Karen Queliza; Sarah Sidhu; Aliza B Solomon; David L Suskind; Madison Weatherly; Steven Werlin; Edwin F de Zoeten; Stacy A Kahn
Journal:  J Crohns Colitis       Date:  2022-06-24       Impact factor: 10.020

Review 4.  Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.

Authors:  Rachel Bernard; Suchitra K Hourigan; Maribeth R Nicholson
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 5.235

5.  Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study.

Authors:  Haiming Fang; Lian Fu; Xuejun Li; Chunxia Lu; Yuan Su; Kangwei Xiong; Lijiu Zhang
Journal:  Microb Cell Fact       Date:  2021-01-19       Impact factor: 5.328

6.  Establishment and resilience of transplanted gut microbiota in aged mice.

Authors:  Ying Wang; Jinhui Tang; Qingqing Lv; Yuxiang Tan; Xiaoxiao Dong; Hongbin Liu; Nannan Zhao; Zhen He; Yan Kou; Yan Tan; Xin-An Liu; Liping Wang; Yang-Yu Liu; Lei Dai
Journal:  iScience       Date:  2021-12-18

Review 7.  Fecal Microbial Transplantation in Critically Ill Patients-Structured Review and Perspectives.

Authors:  Ivana Cibulková; Veronika Řehořová; Jan Hajer; František Duška
Journal:  Biomolecules       Date:  2021-10-04

8.  Long-term outcomes of antibiotic combination therapy for ulcerative colitis.

Authors:  Yuriko Nishikawa; Nobuhiro Sato; Shintaro Tsukinaga; Kan Uchiyama; Shigeo Koido; Dai Ishikawa; Toshifumi Ohkusa
Journal:  Ther Adv Chronic Dis       Date:  2021-07-06       Impact factor: 5.091

Review 9.  Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis.

Authors:  Valentin Mocanu; Sabitha Rajaruban; Jerry Dang; Janice Y Kung; Edward C Deehan; Karen L Madsen
Journal:  J Clin Med       Date:  2021-03-01       Impact factor: 4.241

10.  A Randomized Placebo-Controlled Trial of Combination Therapy With Post-triple-antibiotic-therapy Fecal Microbiota Transplantation and Alginate for Ulcerative Colitis: Protocol.

Authors:  Dai Ishikawa; Xiaochen Zhang; Kei Nomura; Natsumi Seki; Mayuko Haraikawa; Keiichi Haga; Tomoyoshi Shibuya; Yun-Gi Kim; Akihito Nagahara
Journal:  Front Med (Lausanne)       Date:  2022-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.